4.8 Article

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

Journal

CELL
Volume 174, Issue 2, Pages 433-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2018.05.036

Keywords

-

Funding

  1. Department of Defense [W81XWH-17-1-0358]
  2. Prostate Cancer Foundation Young Investigator Award
  3. Canadian Institutes of Health Research [MFE-140389]
  4. Norwegian Cancer Society [PR-2007-0166]
  5. NIH [K08 CA188615, R01CA174777, P01CA163227, R01 CA215489]
  6. NCI [R35 CA197568]
  7. PCF-V Foundation
  8. Movember/PCF
  9. Gerstner Family Foundation
  10. Prostate SPORE [P50CA097186]
  11. Fund for Innovation in Cancer Informatics
  12. American Cancer Society Research Professorship

Ask authors/readers for more resources

Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC), but there have been few whole-genome sequencing (WGS) studies of this disease state. We performed linked-read WGS on 23 mCRPC biopsy specimens and analyzed cell-free DNA sequencing data from 86 patients with mCRPC. In addition to frequent rearrangements affecting known prostate cancer genes, we observed complex rearrangements of the AR locus in most cases. Unexpectedly, these rearrangements include highly recurrent tandem duplications involving an upstream enhancer of AR in 70%-87% of cases compared with < 2% of primary prostate cancers. A subset of cases displayed AR or MYC enhancer duplication in the context of a genomewide tandem duplicator phenotype associated with CDK12 inactivation. Our findings highlight the complex genomic structure of mCRPC, nominate alterations that may inform prostate cancer treatment, and suggest that additional recurrent events in the non-coding mCRPC genome remain to be discovered.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available